Edition:
United States

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

29.55USD
23 May 2018
Change (% chg)

$-0.15 (-0.51%)
Prev Close
$29.70
Open
$29.35
Day's High
$30.25
Day's Low
$29.30
Volume
64,833
Avg. Vol
196,805
52-wk High
$30.25
52-wk Low
$11.55

Latest Key Developments (Source: Significant Developments)

Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
Friday, 20 Apr 2018 05:03pm EDT 

April 20 (Reuters) - Novocure Ltd ::NOVOCURE LTD SAYS EXECUTIVE CHAIRMAN WILLIAM DOYLE'S FY 2017 TOTAL COMPENSATION WAS $23.8 MILLION - SEC FILING.  Full Article

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer
Monday, 18 Dec 2017 07:37am EST 

Dec 18 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER.NOVOCURE LTD - RECEIVED A U.S. FOOD AND DRUG ADMINISTRATION INVESTIGATIONAL DEVICE EXEMPTION APPROVAL TO INITIATE ITS PANOVA 3 CLINICAL TRIAL.  Full Article

Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma
Friday, 1 Dec 2017 07:30am EST 

Dec 1 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA.NOVOCURE-‍JAPANESE MINISTRY OF HEALTH, LABOUR & WELFARE APPROVED RECOMMENDATION TO PROVIDE REIMBURSEMENT FOR OPTUNE TO TREAT NEWLY DIAGNOSED GLIOBLASTOMA​.  Full Article

Novocure reports qtrly ‍loss per share $0.13​
Thursday, 26 Oct 2017 06:00am EDT 

Oct 26 (Reuters) - Novocure Ltd :Novocure Ltd - Qtrly ‍loss per share $0.13​.Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​.  Full Article

Novocure presents second cohort of phase 2 pilot panova trial results suggesting tumor treating fields
Monday, 12 Dec 2016 04:00pm EST 

Novocure Ltd : Says no serious adverse events related to ttfields were reported . Novocure Ltd- nine patients suffered from serious adverse events unrelated to ttfields therapy .Novocure presents second cohort of phase 2 pilot panova trial results suggesting tumor treating fields plus nab-paclitaxel and gemcitabine may be safe as first-line treatment and may improve one-year survival rate of patients with advanced.  Full Article

Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ov
Monday, 12 Dec 2016 04:00pm EST 

Novocure Ltd : Novocure - topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of ttfields in recurrent ovarian cancer .Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ovarian cancer.  Full Article

Novocure reports Q2 financial results
Thursday, 28 Jul 2016 06:30am EDT 

Novocure Ltd : Novocure reports second quarter 2016 financial results and provides company update . Q2 revenue $17.9 million versus I/B/E/S view $16 million .Net losses for three months ended June 30, 2016, were $40.6 million compared to net losses of $29.4 million for same period in 2015.  Full Article

Novocure receives FDA approval for second generation optune system
Wednesday, 13 Jul 2016 04:00pm EDT 

Novocure Ltd : Novocure receives FDA approval for second generation optune system .Says receives FDA approval for second generation optune system.  Full Article

BRIEF-Novocure Reports Qtrly Loss Per Share $0.23

* NOVOCURE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE